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Summary
 
CCR5, a chemokine receptor expressed on T cells and macrophages, is the principal corecep-
tor for M-tropic HIV-1 strains. Recently, we described an NH
 
2
 
-terminal modification of the
CCR5 ligand regulated on activation, normal T cell expressed and secreted (RANTES), ami-
nooxypentane-RANTES (AOP-RANTES), that showed potent inhibition of macrophage in-
fection by HIV-1 under conditions where RANTES was barely effective. To investigate the
mechanism of AOP-RANTES inhibition of HIV infectivity we examined the surface expression
of CCR5 using a monoclonal anti-CCR5 antibody, MC-1. We demonstrate that AOP-RANTES
rapidly caused 
 
.
 
90% decrease in cell surface expression of CCR5 on lymphocytes, monocytes/
macrophages, and CCR5 transfected Chinese hamster ovary (CHO) cells. RANTES also caused
a loss of cell surface CCR5, although its effect was less than with AOP-RANTES. Signifi-
cantly, AOP-RANTES inhibited recycling of internalized CCR5 to the cell surface, whereas
RANTES did not. When peripheral blood mononuclear cells are cultured for prolonged peri-
ods of time in the presence of RANTES, CCR5 expression is comparable to that seen on cells
treated with control medium, whereas there is no CCR5 surface expression on cells cultured in
the presence of AOP-RANTES. Immunofluorescence indicated that both AOP-RANTES and
RANTES induced downmodulation of cell surface CCR5, and that the receptor was redistrib-
uted into endocytic organelles containing the transferrin receptor. When RANTES was removed,
the internalized receptor was recycled to the cell surface; however, the receptor internalized in
the presence of AOP-RANTES was retained in endosomes. Using human osteosarcoma
(GHOST) 34/CCR5 cells, the potency of AOP-RANTES and RANTES to inhibit infection
by the M-tropic HIV-1 strain, SF 162, correlated with the degree of downregulation of CCR5
induced by the two chemokines. These differences between AOP-RANTES and RANTES in
their effect on receptor downregulation and recycling suggest a mechanism for the potent inhi-
bition of HIV infection by AOP-RANTES. Moreover, these results support the notion that
receptor internalization and inhibition of receptor recycling present new targets for therapeutic
agents to prevent HIV infection.
 
C
 
hemokine receptors, members of the heptahelical G
protein–coupled receptor superfamily (GPCRs), act
in concert with CD4 to enable the entry of HIV and sim-
ian immunodeficiency virus (SIV) into target cells. Several
chemokine receptors have been identified in vitro as core-
ceptors for HIV. CCR5 is the major coreceptor for M-tropic
HIV strains (1–3), whereas CXCR4 permits entry of T-tropic
strains (4). Other chemokine receptors, such as CCR2b (5)
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and CCR3 (6), in addition to chemokine receptor-like or-
phan proteins such as STRL33 or Bonzo (7, 8), GRP-15 or
BOB (8, 9), and GRP1 (9), when expressed on CD4-positive
cell lines, can also function as coreceptors for M- and/or
T-tropic HIV strains. A virally encoded seven transmem-
brane domain containing a chemokine receptor, CMV-US28
(10), may also act as a coreceptor in some cases.
The CCR5 ligands regulated on activation, normal T
cell expressed and secreted (RANTES),
 
1
 
 macrophage in-
flammatory protein (MIP)-1
 
a
 
, and MIP-1
 
b
 
 are able to
block infection of M-tropic HIV strains (11). The inhibi-
tion of HIV entry and infection was only partial, and varied
considerably between different M-tropic virus strains and
target cells. Moreover, stimulatory effects of RANTES
during infection of primary monocytes/macrophages have
been reported (12). Several NH
 
2
 
-terminal modifications of
RANTES have been described creating proteins with an-
tagonist properties. Met-RANTES (13), RANTES(9–68;
reference 14), and aminooxypentane (AOP)-RANTES (15)
all antagonize cellular responses induced by chemokines.
They also block infection by HIV-1 (15, 16), but the
chemically modified AOP-RANTES is actually substan-
tially more potent than RANTES itself.
Two theories have been proposed for the mechanism by
which chemokines prevent chemokine receptor–depen-
dent HIV entry. The chemokine could induce receptor
downregulation from the cell surface, thereby removing
the essential coreceptor. Alternatively, either an agonist or
nonsignaling antagonist could sterically hinder the essential
interaction between the HIV envelope glycoprotein-120
protein and the receptor. Inhibition of HIV infectivity by
the three functional chemokine receptor antagonists ini-
tially suggested the second mechanism (15, 16). However,
studies with CXCR4 and CCR5 have suggested that core-
ceptor internalization contributes to efficient chemokine
inhibition of virus entry (17, 18). To investigate which
mechanism AOP-RANTES efficiently inhibits HIV entry,
we determined by FACS
 
Ò
 
 (Becton Dickinson, Mountain
View, CA) analysis the fate of CCR5 after binding of
RANTES, Met-RANTES, or AOP-RANTES on Chi-
nese hamster ovary (CHO) cells, stably transfected with
CCR5, as well as on freshly isolated lymphocytes and mono-
cytes. These three ligands induce varied degrees of down-
regulation of CCR5. However, we show here that the
chemically conjugated AOP-RANTES is highly effective
in preventing recycling of internalized CCR5 to the cell
surface in both transfected CHO cells and primary PBMCs.
Together, our results suggest that ligand-induced intracel-
lular sequestration of HIV coreceptors can inhibit cellular
infection by HIV.
 
Materials and Methods
 
Generation of the CHO/CCR5 Cell Line.
 
The cDNA sequence
of CCR5 was amplified from genomic DNA of human PBMCs
by PCR with Pfu-polymerase (Stratagene Corp., La Jolla, CA),
ligated into the PCR-Script Amp Sk(
 
1
 
) script vector (Stratagene
Corp.), and sequenced. After subcloning into the PEF-DHFR
vector, DHFR-deficient CHO cells were transfected by elec-
troporation and selected for stable expression in nucleoside free
MEM medium with 10% dialyzed FCS as described (19). The
CHO/CCR5 transfected cells were shown to be homogeneous
by FACS
 
Ò
 
 analysis.
 
PBMC Purification.
 
PBMCs were prepared from fresh buffy
coats of healthy blood donors by Ficoll density centrifugation.
Buffy coats were diluted 1:2 in 0.9% NaCl, and 35 ml were lay-
ered onto 15 ml of Ficoll Paque and centrifuged for 25 min at
400 
 
g.
 
 The white interphase was harvested and thrombocytes de-
pleted by three subsequent washing and centrifugation steps at
100 
 
g
 
 for 6 min in RPMI with 10% FCS. Freshly isolated mono-
cytes expressed a very low level of CCR5, but expression was
strongly induced after culture of PBMCs in RPMI with 10% FCS
for 24 to 48 h at 37
 
8
 
C. The amount of FCS did not influence this
induction. The expression of CCR5 on lymphocytes was not al-
tered during culture.
 
Generation of the Monoclonal Anti-CCR5 Antibody.
 
To gener-
ate mAbs against human CCR5, five BALB/c mice were immu-
nized intraperitoneally at 4-wk intervals, first with 10
 
7
 
 PBMCs
cultured for 10 d in IL-2 (100 U/ml) and six subsequent intra-
peritoneal injections of 10
 
7
 
 CHO cells expressing high levels of
CCR5. For this purpose, CCR5 transfected CHO cells were
grown in the presence of 20 nM methotrexate to amplify expres-
sion of CCR5, and one clone expressing high levels of CCR5
was chosen. 4 d after the last intraperitoneal injection of CHO/
CCR5 cells, the spleens were removed and the cells fused with
the P3X63-Ag8 cell line. Supernatants from 
 
z
 
6,000 hybridomas
were screened per fusion by flow cytometry on stable CHO/
CCR5 cells and an mAb against CCR5 (MC-1) was detected af-
ter the third fusion. The specificity of MC-1 (IgG1) was tested on
CHO cells stably transfected with CCR1-4 and CXCR4. In all
cases, no binding was detected. In addition, the antibody did not
react against freshly isolated monocytes and cultured monocytes
from a donor homozygous for the 
 
D
 
32 deletion in the CCR5
gene.
 
Detection of Cell Surface CCR5.
 
5 
 
3
 
 10
 
5
 
 CHO/CCR5 cells
or PBMCs were incubated for 30 min at 37
 
8
 
C with various con-
centrations of chemokines diluted in RPMI with 10% FCS in a
volume of 100 
 
m
 
l. Medium alone was used for controls. Cells
were then cooled to 4
 
8
 
C and, after centrifugation, resuspended in
100 
 
m
 
l supernatant from the MC-1 hybridoma or medium as
negative control. After 30 min at 4
 
8
 
C, cells were washed four
times with PBS and incubated with an FITC-labeled rabbit anti–
mouse F(ab)2 fragment (F313; Dako Corp., Carpinteria, CA) for
30 min at 4
 
8
 
C. After two washing steps, cells were analyzed on
the FACScan
 
Ò
 
. Lymphocytes and monocytes were distinguished
by their forward and side scatter properties. Relative fluorescence
intensity was calculated as (mean channel fluorescence [chemo-
kines] 
 
2
 
 mean channel fluorescence [negative control])/(mean chan-
nel fluorescence [medium] 
 
2
 
 mean channel fluorescence [negative
control]).
 
CCR5 Recycling.
 
To study recycling of CCR5, PBMC or
CHO/CCR5 cells were first incubated for 30 min at 37
 
8
 
C with
100 nM RANTES, 100 nM AOP-RANTES, or medium as con-
trol. Cells were washed four times in medium at room tempera-
 
1
 
Abbreviations used in this paper:
 
 AOP, aminooxypentane; BM, binding
medium; CHO, Chinese hamster ovary; MIP, macrophage inflammatory
protein; RANTES, regulated on activation, normal T cell expressed and
secreted; TfR, transferrin receptor. 
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ture and incubated further at 37
 
8
 
C. Aliquots were taken at the
times indicated, stained, and analyzed as described above. When
cycloheximide was used, cells were preincubated for 20 min with
100 
 
m
 
g/ml cycloheximide, which was also present during the
subsequent procedures.
 
Calcium Mobilization.
 
The ability of the RANTES proteins
to mobilize calcium was determined using 2 
 
3
 
 10
 
6
 
 Fura-2 loaded
CHO/CCR5 cells for each measurement as previously described
(20).
 
Virus Infection Assays.
 
Human osteosarcoma (GHOST) 34/
CCR5 cells are derived from HOS/CD4 cells stably expressing
CCR5 and were a gift from Dan Littman (Skirball Institute, New
York). 2.5 
 
3
 
 10
 
4
 
 cells in 48-well trays were exposed to 100 
 
m
 
l of
chemokine at appropriate dilution for 30 min at 37
 
8
 
C. 100 
 
m
 
l of
the nonsyncytium-inducing (NSI), CCR5-dependent HIV-1 strain,
SF162, was added at 1,000 focus-forming units/ml and the cells
were incubated for a further 3 h. The cells were then washed and
incubated in medium containing the appropriate chemokine for 4 d
before fixing, staining in situ for p24 production, and estimating
foci of infection as previously described (21).
 
Immunofluorescence Microscopy.
 
CHO/CCR5 cells were cul-
tured on glass coverslips in 4-well plates for 48 h. For experi-
ments, the cells were washed in binding medium (BM; RPMI-
1640 without bicarbonate, containing 0.2% BSA and 10 mM Hepes,
pH 7.4) at room temperature. Subsequently, the cells were incubated
in BM or BM containing either RANTES (250 nM), AOP-
RANTES (125 nM), or Met-RANTES (250 nM) at 37
 
8
 
C. At
the indicated times, the coverslips were placed on ice and washed
with cold BM. For recycling, selected coverslips were incubated
for a further hour in BM at 37
 
8
 
C. All cells were then fixed in PBS
containing 3% paraformaldehyde for 10 min. The fixed cells were
washed with PBS, quenched with 50 mM NH
 
4
 
Cl in PBS, and
stained intact or after treatment with 0.05% Saponin for 15 min.
For intact cell staining, antibodies were diluted in PBS con-
taining 0.2% gelatine. Cells were incubated with MC-1 (culture
supernatant 1/10) for 1 h at room temperature and bound anti-
bodies detected using a biotin-conjugated anti–mouse IgG anti-
body (1/100; Amersham Corp., Arlington Heights, IL) and
streptavidin-FITC (1/100; Amersham Corp.). To stain permeabi-
lized cells, the antibodies were diluted in PBS-0.2% gelatine con-
taining 0.05% Saponin. The cells were labeled for 1 h with the
anti-CCR5 mAb 45523.111 (10 
 
m
 
g/ml; R&D Systems Inc.,
Minneapolis, MN) and the anti-transferrin receptor mAb H68.4
(1/100; provided by Dr. Ian Trowbridge, Salk Institute, La Jolla,
CA) or the mAb 3E9 against the lysosomal membrane glycopro-
tein Lgp-B (culture supernatant 1/2; provided by Dr. Bruce
Granger, Montana State University, Bozeman, MO). The cells
were washed in PBS containing 0.05% Saponin and then incu-
bated with a mix of FITC-conjugated anti–mouse IgG
 
2b
 
 (1/100;
Nordic Immunological Laboratories, Maidenhead, UK) and bi-
otin-conjugated anti–mouse IgG
 
1
 
 (1/100; Amersham Corp.) for
30 min at room temperature. Finally, the cells were stained with
streptavidin–Texas red (1/100; Pierce, Chester, UK) for 30 min.
All coverslips were mounted in mowiol and examined using a
microscope (Optiphot-2, Nikon, Melville, NY) equipped with a
laser scanner (MRC 1024; BioRad Labs., Hercules, CA). The im-
ages were assembled in and printed directly from Adobe Photoshop.
 
Results
 
Downregulation of Surface CCR5.
 
CCR5 downregulation
from the surface of CHO/CCR5 cells induced by
RANTES, Met-RANTES, and AOP-RANTES as well as
MIP-1
 
a
 
 and MIP-1
 
b
 
 is shown in Fig. 1. The expression of
CCR5 on the surface of these cells was measured by
FACS
 
Ò
 
 analysis using the CCR5-specific mAb MC-1. Al-
though the natural ligands RANTES, MIP-1
 
a
 
, and MIP-1
 
b
 
effectively caused disappearance of CCR5 from the cell
surface, the downregulation was never 
 
.
 
60% at a concen-
tration of 100 nM. RANTES was more effective than
MIP-1
 
a
 
 and MIP-1
 
b
 
, showing 40% downregulation at 10
nM, whereas a significant downregulation induced by
MIP-1
 
a
 
 and MIP-1
 
b
 
 was only observed at concentrations
 
.
 
30 nM. The two antagonist proteins demonstrated very
different effects. Met-RANTES was very inefficient at re-
ceptor downregulation since at 100 nM only 20% of the
receptors were removed from the surface, whereas AOP-
RANTES at 10 nM caused 80% downregulation and
 
,
 
15% of CCR5 receptors were detectable at 100 nM.
When the experiments were performed at 37
 
8
 
C in the
presence of 1 M sucrose or at 4
 
8
 
C, conditions that in other
systems inhibit receptor internalization (22), the disappear-
ance of surface CCR5 was minimal, indicating that the in-
duced decrease in cell surface CCR5 was due to receptor
internalization and not to ligand-mediated inhibition of
MC-1 binding (data not shown).
The potency of AOP-RANTES to downregulate CCR5
was even more striking when lymphocytes and cultured
monocytes from several different donors were studied. Re-
ceptor loss was readily detectable after 5 min (data not
shown) and reached a maximum after 20–30 min. Repre-
sentative experiments are shown in Fig. 2. Using PBMCs
from several different donors, AOP-RANTES caused
 
.
 
95% downregulation of CCR5 from lymphocytes and
Figure 1. Downregulation of CCR5 from the surface of stably trans-
fected CHO cells. CHO-CCR5 cells were incubated for 30 min at 378C
with the concentrations indicated of the different chemokines: RANTES
(d), MIP-1a ( m ), MIP-1b ( . ), AOP-RANTES (j), and Met-
RANTES (r). Surface CCR5 was detected with a monoclonal CCR5
antibody (MC-1) and analyzed by flow cytometry. No downregulation
was observed with monocyte chemotactic protein (MCP)-1, MCP-2,
Gro-a, and SDF-1a at a concentration of 100 nM (data not shown). 
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monocytes, whereas RANTES only achieved about 60–
70% reduction on these primary cells.
To examine the fate of internalized CCR5, RANTES–
and AOP-RANTES–treated lymphocytes and monocytes
were assessed for cell surface CCR5 expression after recul-
ture after removal of the chemokine from the culture me-
dium. As shown in Fig. 3, receptor cell surface expression
returned to control levels after removal of RANTES. In
contrast, surface reexpression of CCR5 was significantly
lower after removal of AOP-RANTES. The experiments
were performed with PBMCs from five donors. Exposure
of PBMCs to AOP-RANTES from these donors resulted
in 25–30% recycling compared to that of controls, whereas
only 15% recycling was observed for the fourth, and 40%
for the fifth. However, in the case of RANTES exposure,
the receptor recycling consistently attained almost 100% of
controls. To investigate whether the reappearance of CCR5
on the cell surface was due to de novo synthesis of the re-
ceptor, the experiments were repeated in the presence cy-
cloheximide at a concentration of 100 
 
m
 
g/ml. The results
were identical to those shown in Fig. 3. Recycled receptors
were not refractory to internalization, as they could be
downregulated by a second exposure to RANTES or AOP-
RANTES (data not shown).
The most impressive observation was the result of pro-
longed incubation of PBMC for up to 12 d in the presence
of either RANTES or AOP-RANTES (Fig. 4). Cells cul-
tured in the presence of 100 nM RANTES showed normal
levels of surface expression CCR5. However, no CCR5-
positive cells were observed when the cells were cultured
with the same concentration of AOP-RANTES.
 
Morphological Examination of CCR5 Internalization.
 
To fur-
ther eliminate the possibility that the apparent disappear-
ance of surface CCR5 was due to alteration of the MC-1
epitope induced by ligand binding, we examined CCR5
downmodulation morphologically. CHO/CCR5 cells,
grown on glass coverslips, were treated with RANTES,
AOP-RANTES, or Met-RANTES for 30 min at 37
 
8
 
C.
Subsequently, the cells were fixed and cell surface CCR5
expression was determined using the anti-CCR5–specific
mAb MC-1. Fig. 5 shows that cells incubated in medium
alone (
 
a
 
) show prominent CCR5 cell surface expression.
On cells treated with RANTES or AOP-RANTES, signif-
icantly less CCR5 staining was seen (
 
c
 
 and 
 
d
 
, respectively).
By contrast, Met-RANTES induced little change in cell
surface CCR5 expression compared to cells treated with
medium alone (
 
b
 
).
Since removal of RANTES, but not AOP-RANTES,
allowed reappearance of the receptor on the cell surface af-
Figure 2. Downregulation of CCR5 on lymphocytes (open symbols)
and monocytes (solid symbols). PBMCs were incubated with various con-
centrations of RANTES (circles) and AOP-RANTES (squares) for 30 min
at 378C, labeled with a monoclonal CCR5 antibody (MC-1), and ana-
lyzed as described. It is noteworthy that PBMCs were cultured for 24 h at
378C in RPMI with 10% FCS. This procedure strongly induces expres-
sion of CCR5 on monocytes, whereas expression on lymphocytes was
unchanged (data not shown).
Figure 3. Recycling of CCR5 on lymphocytes (open symbols) and
monocytes (closed symbols) after downregulation with RANTES (circles)
and AOP-RANTES (squares). PBMCs were first incubated for 30 min at
378C with 100 nM RANTES or AOP-RANTES. After downregulation,
the chemokines were removed by four washing steps with medium, and
cells were further cultured in medium at 378C for various periods of time
and analyzed for CCR5 expression as described above.
Figure 4. Histogram analysis showing the surface expression of CCR5
on lymphocytes after 12 d of incubation with 100 nM RANTES and
AOP-RANTES. CCR5 expression was measured as described in Fig. 2.
Incubation with medium (solid line), 100 nM RANTES (dotted line), or
100 nM AOP-RANTES (dashed line). Shaded area, secondary antibody
alone.1219 Mack et al.
ter downmodulation (Fig. 3), we examined RANTES–
and AOP-RANTES–treated cells for surface CCR5 ex-
pression after reincubation in ligand-free medium for 1 h at
378C. Fig. 5, c9 shows that after removal of RANTES,
CCR5 reappeared at the cell surface. By contrast, in cells
treated with AOP-RANTES, there was no observable re-
covery of cell surface receptor over the 1-h incubation
period (d9). Together, these observations support the bio-
chemical data indicating that RANTES and AOP-RANTES,
but not Met-RANTES, can induce downmodulation of
cell surface CCR5. Moreover, AOP-RANTES prevents
the recycling of the receptor seen after removal of
RANTES.
To determine whether the loss of cell surface CCR5 was
due to internalization of the receptor, we examined the
distribution of CCR5 on permeabilized cells after treat-
ment with RANTES and AOP-RANTES. As illustrated
above, cells incubated in medium alone showed prominent
cell surface staining and little intracellular CCR5 staining
(Fig. 6, a and d, green fluorescence). However, after treatment
with RANTES or AOP-RANTES for 1 h, the cell surface
staining was reduced considerably and prominent intracel-
lular vesicular staining was seen (Fig. 6, b, c, e, and f ). In
many cells, the vesicles were observed both in the periph-
ery of the cell and in a cluster in the perinuclear region. To
determine the nature of these internal vesicles, we costained
cells with antibodies to either the transferrin receptor (TfR)
that marks early endosomes (Fig. 6, a, b, and c, red) or a ly-
sosomal membrane glycoprotein lgp-B that marks late en-
dosomes and lysosomes (d, e, and f, red). In cells treated
with either RANTES or AOP-RANTES, some vesicles
appeared that were either stained for CCR5 or TfR alone.
However, we saw significant overlap of these two labels in-
dicated in yellow (Fig. 6, b and c). In contrast, in cells costained
for CCR5 and lgp-B, virtually all of the stained structures
were either green or red, indicating little overlap in the dis-
tribution of the two proteins (Fig. 6, e and f ). Together,
these data indicate (a) that the downmodulation of cell sur-
face CCR5 by RANTES and AOP-RANTES is due to
ligand-induced internalization of the receptor and (b) that
the receptors internalized by both RANTES and AOP-
RANTES appear to be largely associated with TfR con-
taining early endosomes. No indication of the transfer of
the receptors to lysosomes was seen, though we cannot ex-
clude the possibility that some receptors were delivered to
lysosomes and were rapidly degraded. However, within the
time course of these experiments we saw no detectable loss
of fluorescence signal. Moreover, in pulse chase experi-
ments in which cells were treated with RANTES or AOP-
RANTES for 1 h and then reincubated in ligand-free me-
dium for a further hour, no colocalization of CCR5 with
the lysosomal marker was observed (data not shown).
Receptor Activation. The ability of a ligand to downreg-
ulate its receptor depends on its ability to cause receptor ac-
tivation. Modification of the NH2 terminus of RANTES
has been reported by us and others to abrogate agonist ac-
tivity, as judged by their capacity to elicit calcium mobili-
zation and induce chemotaxis (13, 14). However, the abil-
ity of AOP-RANTES and RANTES(9–68) to induce
receptor internalization indicates that these proteins are ca-
pable of receptor activation. Since the studies of agonist ac-
tivity were performed on the promonocytic cell line,
THP-1 (for Met-RANTES; reference 13) and freshly iso-
lated monocytes (for AOP-RANTES; reference 15) where
receptor expression may have been too low to allow signal
detection, we decided to investigate the capacity of these
ligands to mobilize calcium in cells expressing high levels of
CCR5. As shown in Fig. 7, both modified proteins were
capable of causing calcium mobilization, although neither
achieved the potency and efficacy of RANTES itself. Met-
RANTES was clearly the least effective in receptor activa-
tion, mirroring its inefficient downregulation of CCR5
and its inability to cause internalization of CCR1 in CHO
cells (23).
Inhibition of Viral Infectivity. CCR5 downregulation was
analyzed on GHOST 34/CCR5 cells in parallel with in-
fection by the M-tropic HIV-1 strain, SF 162. Upon incu-
bation with 100 nM RANTES, no internalization of
CCR5 was observed in these cells after 30 min of incuba-
tion, but after 3.5 h, 50% internalization could be detected
(Fig. 8 A). In contrast, z50% of CCR5 receptors were in-
ternalized after 30 min of incubation with AOP-RANTES
and no receptors were detectable after 3.5 h (Fig. 8 B). The
inhibition of viral infection by the M-tropic strain SF 162
(Fig. 8 C) correlated very well with the loss of CCR5 surface
receptors induced by AOP-RANTES, whereas RANTES
showed almost no inhibition of infection. AOP-RANTES
caused almost 90% inhibition at 125 nM, which corre-
sponds well to the degree of removal of cell surface CCR5
seen on monocytes and lymphocytes shown in Fig. 2. Al-
though 100 nM RANTES induces 70% CCR5 downregu-
lation over 30 min, the recycling experiments shown in
Fig. 3 may explain why inhibition of infection by RANTES
only starts to be effective at higher concentrations.
Discussion
It is now clearly established that chemokine receptors are
required for primate lentiviruses to fuse with and infect tar-
get cells either in combination with CD4 (24, 25) or inde-
pendently (26, 27). Furthermore, it is clear that under cer-
tain circumstances agonistic and antagonistic ligands for
these receptors can inhibit virus entry (11, 15, 16, 28).
However, the precise mechanism through which these
agents inhibit infection remains to be established. Two
models have been proposed (29). The first proposes that
the binding of the ligand to the requisite chemokine recep-
tor sterically blocks the interaction of the viral envelope, or
envelope–CD4 complex. Initial experiments performed
with antagonists that were described as nonsignaling (15,
16) suggested that this might be the prime mode of action.
The second model proposes that chemokine receptor
ligands induce internalization of the coreceptor molecule
from the cell surface, thereby removing a key element of
the fusion complex. Two recent studies examining the ability
of stromal cell–derived factor (SDF)-1 to block CXCR4-1220 A Novel Inhibitory Mechanism of HIV Infectivity1221 Mack et al.
dependent virus entry have concluded that receptor inter-
nalization may, in fact, contribute to efficient inhibition of
virus infection, although steric effects are not excluded by
these studies (17, 18). Furthermore, Amara et al. (17) showed
that the antagonist RANTES(9–68), although having been
previously reported not to cause receptor activation as es-
timated by its inability to mobilize calcium and induce
chemotaxis (14), was in fact able to induce downregulation
of cell surface CCR5.
We have shown that chemical modification of the NH2
terminus of RANTES to form AOP-RANTES, while
producing a potent antagonist of RANTES– and MIP-1b–
induced monocyte chemotaxis (15), is very potent in in-
ducing downregulation of surface CCR5. Furthermore, the
downregulation of CCR5 achieved by AOP-RANTES is
significantly higher than with the agonist, both in CHO
cells and in freshly isolated primary cells such as lympho-
cytes and monocytes. Met-RANTES, on the other hand,
was only able to weakly downregulate surface CCR5. In
general, internalization of the G protein–coupled receptor
superfamily is believed to require binding of an agonist to
the receptor in order to activate the events that initiate re-
ceptor endocytosis (for reviews see references 30 and 31).
In brief, this pathway is initiated by phosphorylation of the
intracellular COOH-terminal domain by G protein recep-
tor kinases and subsequent interaction with the arrestin
proteins causing sequestration of the phosphorylated recep-
tors into clathrin-coated pits. Thus, receptor internalization
is an agonist-driven event, and the NH2-terminally modified
RANTES ligands that are able to drive receptor downreg-
ulation must be able to activate the receptor. We have now
shown that on CHO cells that express high numbers of re-
combinant receptors, G protein coupling, as indicated by
calcium mobilization, is in fact measurable. However, it
should be noted that the relative efficacies of AOP-RANTES
and RANTES in eliciting downregulation of CCR5 do
not correlate with their capacity to mobilize calcium. In
both calcium mobilization and downregulation of CCR5,
Met-RANTES is the least potent, and we previously re-
ported that it was not able to cause internalization of
CCR1 in CHO/CCR1 cells (23).
The enhanced potency of AOP-RANTES in receptor
downregulation may be explained by its greater affinity for
CCR5. It has been shown to have significantly different
binding properties to CCR5 expressed in human embry-
onic kidney (HEK) 293 cells compared to both RANTES
and Met-RANTES (15). RANTES and Met-RANTES
show biphasic binding to the receptor, and are not able to
completely compete for the radiolabeled ligand at a con-
centration of 100 nM. AOP-RANTES achieves complete
competition at 10 nM, and shows a single phase competi-
tion curve. These binding characteristics are identical when
the receptor is expressed in CHO cells (T. Schwartz, un-
published results). This difference in affinity could there-
fore explain, in part, the significantly increased potency of
AOP-RANTES to induce CCR5 downregulation though
the means by which this increase in binding affinity affects
the endocytic trafficking of the CCR5 molecule has still to
be established.
To our knowledge, this is the first report of inhibition of
recycling of a receptor that normally will reappear on the
cell surface after removal of the ligand. Although endocy-
tosis of the chemokine receptors has not been studied in
great detail to date, there is evidence that these receptors
can either recycle or enter a degradation pathway via the
lysosomal compartment. CXCR4 has been shown to recy-
cle to the surface after both phorbol ester and SDF-1 in-
duced endocytosis (17, 18), as we have also shown here for
CCR5. On the other hand, CXCR2 has been reported to
undergo degradation after internalization (32). It is believed
that recycling of the receptors from endocytic organelles
requires dissociation of the ligand from the receptor and
subsequent dephosphorylation. The reason why AOP-
Figure 5. Downmodulation and recycling of CCR5. CHO/CCR5 cells were treated with medium (a) or medium containing either RANTES (250
nM; c and c9), AOP-RANTES (125 nM; d and d9), or Met-RANTES (250 nM; b) for 30 min at 378C. The cells were then cooled on ice, washed ex-
tensively in cold medium, and either held on ice or reincubated at 378C for a further 60 min in medium (c9 and d9). Subsequently, all cells were fixed and
labeled with the anti-CCR5 mAb MC1. Bar, 40 mm.
Figure 6. Intracellular localization of downmodulated CCR5. CHO/CCR5 were treated with medium (a and d), medium with RANTES (250 nM;
b and e), or AOP-RANTES (125 nM; c and f ) for 1 h at 378C. After fixation and permeabilization, the cells were costained for CCR5 (green) and TfR (a,
b, and c; red) or a lysosomal marker Lgp-B (d, e, and f; red). Scale bar, 40 mm.
Figure 7. The induction of calcium mobilization induced by RANTES
(d), AOP-RANTES (j), and Met-RANTES (r) in CHO/CCR5 cells.
Calcium mobilization was determined as previously described (25) using 2 3
106 Fura-2–loaded cells for each measurement, with the concentration of
chemokine as indicated.1222 A Novel Inhibitory Mechanism of HIV Infectivity
RANTES prevents this process from occurring is not clear,
and effects other than the greater affinity for the receptor
will be subject for further investigation.
Receptor internalization is not directly responsible for
the entry of the HIV virus into the cell (33), since mutant
CCR5 molecules that prevent receptor endocytosis can still
function as a coreceptor for viral entry (17, 18, 34). How-
ever, our results suggest that molecules that induce inter-
nalization and subsequently interfere with recycling of
chemokine receptors contribute significantly to the inhibi-
tion of HIV-1 infectivity. An approach based on gene tar-
geting in which the CCR5 ligands, RANTES, and MIP-1a
are modified such that a KDEL sequence added to their
COOH terminus prevents a newly synthesized receptor
from trafficking from the endoplasmic reticulum to the cell
surface renders these cells resistant to HIV infection (35).
Support for the notion that anti-HIV therapeutics aimed
at removing cell surface CCR5 will be well tolerated and
without significant side effects is suggested by the apparent
healthy state of individuals homozygous for the D32 CCR5
allelle who appear highly resistant to HIV infection (36).
Although adverse effects of this D32 CCR5 allele in the
rate of mortality after infection have been suggested (37), a
therapy based on prevention of CCR5 recycling could be
envisaged in conjunction with the other therapies currently
in use. To this end we are continuing to elucidate the bio-
chemical and cellular mechanisms through which AOP-
RANTES prevents CCR5 recycling.
Figure 8. Downregulation of CCR5 from the surface of GHOST 34/
CCR5 cells and the inhibition of their infection by the M-tropic HIV-1
strain SF 162 by RANTES and AOP-RANTES. (A) Downregulation of
CCR5 induced by 100 nM RANTES. The medium control is shown by
the solid line and surface expression of CCR5 after 30 min by the dotted
line and after 3.5 h by the dashed line. (B) Downregulation of CCR5 in-
duced by 100 nM AOP-RANTES. The medium control is shown by the
solid line and the surface expression of CCR5 after 30 min by the dotted
line and after 3.5 h by the dashed line. (C) The inhibition of infection of
GHOST 34/CCR5 cells by SF 162 by increasing concentrations of
RANTES (hatched bars) and AOP-RANTES (solid bars).
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